AT7519 HCl | Multi CDK inhibitor

AT7519 chemical structure

Available Options

Size:PriceQuantity 
5 mg$50.00
25 mg$150.00
Request Quote / Bulk / Custom Size
Product Inquiry

AT7519 (902135-91-5) is a potent CDK inhibitor.  Inhibits CDKs 1,2,4,5,6, and 9 (IC50s respectively: 210 nM, 47 nM, 100 nM, 13 nM, 170 nM, and <10 nM).1,2 Active in multiple human cancer cell lines.3-7 AT7519 has also been found to be a human RORγt agonist.8

References/Citations:

  1. Wyatt et al. (2008), Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design; J. Med. Chem. 51 4986
  2. Squires et al. (2009); Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines, Mol. Cancer Ther., 8 324
  3. Do et al. (2020); Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors, Cancer Chemother. Pharmacol., 86 815
  4. Wang et al. (2022); The cyclin-dependent kinase inhibitor AT7519 augments cisplatin’s efficacy in ovarian cancer via multiple oncogenic signaling pathways, Fundam. Clin. Pharmacol., 36 81
  5. Zhou et al. (2022); AT7519 against lung cancer via the IL6/STAT3 signaling pathway, Biochem. Biophys. Res. Commun., 609 31
  6. Zhao et al. (2023); The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest, Cell Death Dis., 14 11
  7. Karas et al. (2023); Anti-hepatocellular carcinoma activity of the cyclin-dependent kinase inhibitor AT7519, Biomed. Pharmacother., 164 115002
  8. Karas et al. (2025), The cyclin-dependent kinase inhibitor AT7519 is a human RORγt agonist; Immunol. Cell Biol. 103 317
902135-91-5, AT-7519, AT7519, AT7519 HCl, AT7519 hydrochloride, AT7519 supplier, CDK inhibitor

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

AT7519 (902135-91-5) is a potent CDK inhibitor.  Inhibits CDKs 1,2,4,5,6, and 9 (IC50s respectively: 210 nM, 47 nM, 100 nM, 13 nM, 170 nM, and <10 nM).1,2 Active in multiple human cancer cell lines.3-7 AT7519 has also been found to be a human RORγt agonist.8

References/Citations:

  1. Wyatt et al. (2008), Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design; J. Med. Chem. 51 4986
  2. Squires et al. (2009); Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines, Mol. Cancer Ther., 8 324
  3. Do et al. (2020); Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors, Cancer Chemother. Pharmacol., 86 815
  4. Wang et al. (2022); The cyclin-dependent kinase inhibitor AT7519 augments cisplatin’s efficacy in ovarian cancer via multiple oncogenic signaling pathways, Fundam. Clin. Pharmacol., 36 81
  5. Zhou et al. (2022); AT7519 against lung cancer via the IL6/STAT3 signaling pathway, Biochem. Biophys. Res. Commun., 609 31
  6. Zhao et al. (2023); The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest, Cell Death Dis., 14 11
  7. Karas et al. (2023); Anti-hepatocellular carcinoma activity of the cyclin-dependent kinase inhibitor AT7519, Biomed. Pharmacother., 164 115002
  8. Karas et al. (2025), The cyclin-dependent kinase inhibitor AT7519 is a human RORγt agonist; Immunol. Cell Biol. 103 317